

Simon F Lacey

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8561162/simon-f-lacey-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

64
papers

14,316
citations

37
h-index

71
g-index

71
ext. papers

18,644
ext. citations

15.8
avg, IF

5.94
L-index

#	Paper	IF	Citations
64	Decade-long leukaemia remissions with persistence of CD4 CAR T cells.. <i>Nature</i> , 2022 ,	50.4	30
63	An NK-like CAR T cell transition in CAR T cell dysfunction. <i>Cell</i> , 2021 , 184, 6081-6100.e26	56.2	15
62	B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy. <i>British Journal of Haematology</i> , 2021 , 193, 851-855	4.5	0
61	Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. <i>Nature Medicine</i> , 2021 , 27, 842-850	50.5	22
60	CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	15
59	Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma. <i>Frontiers in Oncology</i> , 2021 , 11, 669071	5.3	8
58	Autologous CD4+ T Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals. <i>Molecular Therapy</i> , 2021 , 29, 626-635	11.7	0
57	BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	6
56	The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021 , 27, 6580-6590	12.9	1
55	Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. <i>Blood</i> , 2021 ,	2.2	10
54	Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome. <i>Blood</i> , 2020 , 136, 1980-1983	2.2	7
53	First Trial of CRISPR-Edited T cells in Lung Cancer. <i>Trends in Molecular Medicine</i> , 2020 , 26, 713-715	11.5	7
52	CRISPR-engineered T cells in patients with refractory cancer. <i>Science</i> , 2020 , 367,	33.3	448
51	Systemic Endothelial Activation Is Associated With Early Acute Respiratory Distress Syndrome in Children With Extrapulmonary Sepsis. <i>Critical Care Medicine</i> , 2020 , 48, 344-352	1.4	11
50	CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. <i>Journal of Clinical Investigation</i> , 2020 , 130, 673-685	15.9	45
49	Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma. <i>Onc Immunology</i> , 2020 , 9, 1676615	7.2	15
48	Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventions 2020 ,		52

47	Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2020 , 38, 415-422	2.2	80
46	Stable HLA antibodies following sustained CD19+ cell depletion implicate a long-lived plasma cell source. <i>Blood Advances</i> , 2020 , 4, 4292-4295	7.8	5
45	Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. <i>Science</i> , 2020 , 369,	33.3	744
44	Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. <i>Molecular Therapy</i> , 2020 , 28, 2367-2378	11.7	13
43	Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. <i>Blood Advances</i> , 2020 , 4, 5174-5183	7.8	10
42	Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2862-2871	22.2	45
41	Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies. <i>Blood Advances</i> , 2019 , 3, 2487-2490	7.8	23
40	Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. <i>Molecular Therapy</i> , 2019 , 27, 1919-1929	11.7	101
39	B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. <i>Journal of Clinical Investigation</i> , 2019 , 129, 2210-2221	15.9	312
38	First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma. <i>Blood</i> , 2019 , 134, 49-49	2.2	7
37	Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma. <i>Blood</i> , 2019 , 134, 1863-1863	2.2	13
36	Engineered T Cell Therapies from a Drug Development Viewpoint. <i>Engineering</i> , 2019 , 5, 140-149	9.7	7
35	Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. <i>Nature Medicine</i> , 2018 , 24, 563-571	50.5	649
34	Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. <i>Gastroenterology</i> , 2018 , 155, 29-32	13.3	209
33	Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. <i>JCI Insight</i> , 2018 , 3,	9.9	250
32	Reducing Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells. <i>Cancer Immunology Research</i> , 2018 , 6, 1100-1109	12.5	105
31	Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. <i>Molecular Therapy</i> , 2018 , 26, 269-279	11.7	63
30	Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. <i>JCI Insight</i> , 2018 , 3,	9.9	90

29	CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success. <i>Frontiers in Immunology</i> , 2018 , 9, 2740	8.4	45
28	Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma. <i>Onc Immunology</i> , 2018 , 7, e1468956	7.2	60
27	Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. <i>Nature Medicine</i> , 2018 , 24, 1499-1503	50.5	286
26	Neurotoxicity after CTL019 in a pediatric and young adult cohort. <i>Annals of Neurology</i> , 2018 , 84, 537-546	9.4	49
25	Dominant-Negative TGF- β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. <i>Molecular Therapy</i> , 2018 , 26, 1855-1866	11.7	247
24	Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. <i>Nature</i> , 2018 , 558, 307-312	32.4	362
23	PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. <i>Blood</i> , 2017 , 129, 1039-1041	2.2	285
22	Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. <i>Blood</i> , 2017 , 130, 2317-2325	2.2	180
21	A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	697
20	Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. <i>New England Journal of Medicine</i> , 2017 , 377, 2545-2554	59.2	951
19	Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer. <i>Cancer Immunology Research</i> , 2017 , 5, 1152-1161	12.5	181
18	Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. <i>PLoS Pathogens</i> , 2017 , 13, e1006613	7.6	68
17	Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. <i>Blood</i> , 2016 , 128, 360-70	2.2	143
16	The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. <i>Clinical Cancer Research</i> , 2016 , 22, 2684-96	12.9	108
15	Biomarkers of Response to Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016 , 128, 57-57	2.2	14
14	Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide. <i>Blood</i> , 2016 , 128, 5702-5702	2.2	23
13	Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma. <i>Blood</i> , 2016 , 128, 974-974	2.2	27
12	Pilot study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2067-2067	2.2	14

11	Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3011-3011	2.2	74
10	Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. <i>Journal of Immunological Methods</i> , 2016 , 434, 1-8	2.5	108
9	Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. <i>Cancer Discovery</i> , 2016 , 6, 664-79	24.4	603
8	Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. <i>Blood</i> , 2016 , 127, 1117-27	2.2	282
7	NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. <i>Nature Medicine</i> , 2015 , 21, 914-921	50.5	543
6	Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. <i>Science Translational Medicine</i> , 2015 , 7, 303ra139	17.5	1071
5	Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. <i>Cancer Discovery</i> , 2015 , 5, 1282-95	24.4	713
4	Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015 , 373, 1040-7	59.2	417
3	IMCT-15PILOT STUDY OF T CELLS REDIRECTED TO EGFRvIII WITH A CHIMERIC ANTIGEN RECEPTOR IN PATIENTS WITH EGFRvIII+ GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2015 , 17, v110.4-v111	1	9
2	Chimeric antigen receptor T cells for sustained remissions in leukemia. <i>New England Journal of Medicine</i> , 2014 , 371, 1507-17	59.2	3305
1	Biomarkers in T-cell therapy clinical trials. <i>Cytotherapy</i> , 2013 , 15, 632-40	4.8	6